End products of glycation (AGEs) and inflammation in the clinic of cardiovascular complications and vascular calcification at different stages of chronic kidney disease (G1–G5D)
- Authors: Fatima D.U.1, Remizov O.V.1, Ikoeva Z.R.1, Tedeeva I.V.1, Gusalov A.A.2, Goloeva V.G.3
-
Affiliations:
- North-Ossetia State Medical Academy
- Beslan branch №5 of North Caucasus Nephrology Center LLC
- Republican Clinical Hospital
- Issue: Vol 96, No 6 (2024): Нефрология
- Pages: 593-599
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/260072
- DOI: https://doi.org/10.26442/00403660.2024.06.202727
- ID: 260072
Cite item
Full Text
Abstract
Aim. To clarify the role of advanced glycation end products (AGEs) and inflammation in the development of vascular calcification and cardiovascular complications at different stages of chronic kidney disease (CKD) G1–G5D.
Materials and methods. We examined 105 patients aged 19 to 75 years with stage C1–C5D CKD, 77 (74%) of whom were patients with diabetic nephropathy. The concentration of AGEs, interleukin (IL)-1, IL-6 and tumor necrosis factor α (TNF-α), troponin I, parathyroid hormone was determined by enzyme-linked immunosorbent assay (ELISA) using kits from BluGene biotech (Shanghai, China), Cloud-Clone Corp. (USA), ELISA Kit (Biomedica, Austria).
Results. A high content of AGEs, IL-1, IL-6, TNF-α was established, which directly correlated with the increase in renal failure and changes in the morpho-functional parameters of the left ventricle and aorta.
Conclusion. An increase in serum concentrations of AGEs and inflammatory mediators, correlating with a decrease in renal function and changes in the morpho- functional parameters of the left ventricle and aorta, indicate their significant role in the processes of damage to the cardiovascular system in CKD.
Full Text
##article.viewOnOriginalSite##About the authors
Dzgoeva U. Fatima
North-Ossetia State Medical Academy
Author for correspondence.
Email: fdzgoeva@mail.ru
ORCID iD: 0000-0002-7314-9063
д-р мед. наук, проф. каф. внутренних болезней №5
Russian Federation, VladikavkazOleg V. Remizov
North-Ossetia State Medical Academy
Email: fdzgoeva@mail.ru
ORCID iD: 0000-0003-4175-5365
д-р мед. наук, доц., проф. каф. лучевой диагностики с лучевой терапией и онкологией, ректор
Russian Federation, VladikavkazZarina R. Ikoeva
North-Ossetia State Medical Academy
Email: fdzgoeva@mail.ru
ORCID iD: 0000-0002-4183-2335
аспирант каф. внутренних болезней №5
Russian Federation, VladikavkazIlona V. Tedeeva
North-Ossetia State Medical Academy
Email: fdzgoeva@mail.ru
ORCID iD: 0009-0002-6732-3050
аспирант каф. внутренних болезней №5
Russian Federation, VladikavkazAzamat A. Gusalov
Beslan branch №5 of North Caucasus Nephrology Center LLC
Email: fdzgoeva@mail.ru
ORCID iD: 0009-0002-6296-9688
врач-нефролог диализного центра Бесланского филиала №5
Russian Federation, BeslanVictoria G. Goloeva
Republican Clinical Hospital
Email: fdzgoeva@mail.ru
ORCID iD: 0000-0001-5310-889X
врач-нефролог отд-ния нефрологии
Russian Federation, VladikavkazReferences
- Dozio E, Caldiroli L, Molinari P, et al. Accelerated AGEing: the impact of advanced glycation end products on the prognosis of chronic kidney disease. Antioxidants. 2023;12(3):584. doi: 10.3390/antiox12030584
- Steenbeke M, Speeckaert R, Desmedt S, et al. The role of advanced glycation end products and its soluble receptor in kidney diseases. Int J Mol Sci. 2022;23(7):3439. doi: 10.3390/ijms23073439
- Kırkgöz T, Acar S, Küme T, et al. Evaluation of serum advanced glycation end product levels and microvascular complications in children and adolescents with type 1 diabetes mellitus. Turk Arch Pediatr. 2024;59(1):31-7. doi: 10.5152/TurkArchPediatr.2024.23147
- Shimoike T, Inoguchi Т, Umeda F, et al. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism. 2000;49(8):1030-5. doi: 10.1053/meta.2000.7738
- Tezuka Y, Nakaya I, Nakayama K, et al. Methylglyoxal as a prognostic factor in patients with chronic kidney disease. Nephrology (Carlton). 2019;24(9):943-50. doi: 10.1111/nep.13526
- Sun H, Chen J, Hua Y, et al. new insights into the role of empagliflozin on diabetic renal tubular lipid accumulation. Diabetol Metab Syndr. 2022;14(1):121. doi: 10.1186/s13098-022-00886-x
- Calviño J, Cigarran S, Gonzalez-Tabares L, et al. Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant. PLoS One. 2018;13(8):e0201118. doi: 10.1371/journal.pone.0201118
- Nediani C, Dinu M. Oxidative stress and inflammation as targets for novel preventive and therapeutic approaches in non-communicable diseases II. Antioxidants (Basel). 2022;11(5):824. doi: 10.3390/antiox11050824
- Fotheringham AK, Gallo LA, Borg DJ, Forbes JM. Advanced glycation end products (AGEs) and chronic kidney disease: Does the modern diet AGE the kidney? Nutrients. 2022;14(13):2675. doi: 10.3390/nu14132675
- Dozio E, Vettoretti S, Lungarella G, et al. Sarcopenia in chronic kidney disease: Focus on advanced glycation end products as mediators and markers of oxidative stress. Biomedicines. 2021;9(4):405. doi: 10.3390/biomedicines9040405
- Jeong J, Cho S, Seo M, et al. Soluble RAGE attenuates AngII-induced arterial calcification via inhibiting AT1R-HMGB1-RAGE axis. Atherosclerosis. 2022;346:53-62. doi: 10.1016/j.atherosclerosis.2022.02.022
- Liu B, Sun T, Li H, et al. Proximal tubular RAGE mediated the renal fibrosis in UUO model mice via upregulation of autophagy. Cell Death Dis. 2022;13(4):399. doi: 10.1038/s41419-022-04856-z
- Zhang J, Han X, Chang J, et al. Soluble RAGE attenuates myocardial I/R injuries via FoxO3-Bnip3 pathway. Cell Mol Life Sci. 2022;79(5):269. doi: 10.1007/s00018-022-04307-0
- Hörner DV, Taal MW. Skin autofluorescence: An emerging biomarker in persons with kidney disease. Curr Opin Nephrol Hypertens. 2019;28(6):507-12. doi: 10.1097/MNH.00000000000000549
![](/img/style/loading.gif)